53678-77-6
中文名称
佐剂肽
英文名称
Muramyl Dipeptide
CAS
53678-77-6
EINECS 编号
258-696-9
分子式
C19H32N4O11
MDL 编号
MFCD00077638
分子量
492.48
MOL 文件
53678-77-6.mol
更新日期
2024/04/23 15:25:20
53678-77-6 结构式
基本信息
中文别名
佐剂肽 英文别名
AC-MURAMYL-ALA-D-GLNAC-MURAMYL-ALA-D-GLU-NH2
AC-MURAMYL-ALA-D-ISOGLN-OH
AC-MURAMYL-ALA-D-ISOGLUTAMINE
ADJUVANT PEPTIDE
MDP
MURAMYL DIPEPTIDE
N-ACETYL-MURAMYL-L-ALA-D-ISOGLN
N-ACETYLMURAMYL-L-ALA-D-ISOGLUTAMINE
N-ACETYLMURAMYL-L-ALANYL-D-ISOGLUTAMINE
N-AC-MURAMYL-ALA-D-GLU-NH2
N-AC-MURAMYL-ALA-D-GLU-NH2 2H2O
acetylmuramyl-alanyl-isoglutamine
n(sup2)-(n-(n-acetylmuramoyl)-l-alanyl)-d-alpha-glutamin
n(sup2)-(n-(n-acetylmuramoyl)-l-alanyl)-d-alpha-glutamine
N2-[N-(N-acetylmuramoyl)-L-alanyl]-D-alpha-glutamine
N-Acetylmuramyl-L-alanyl-D-isoglnamine hydrate
n-acetylmuramyl-l-alanyl-d-isoglutamine hydrate
Adjuvant Peptide, Muramyl dipeptide
L-18-MDP
物理化学性质
比旋光度D25 +44° (acetic acid)
沸点1071.8±65.0 °C(Predicted)
密度1.390±0.06 g/cm3(Predicted)
储存条件−20°C
溶解度H2O: 10 mg/mL, clear, colorless
酸度系数(pKa)4.44±0.10(Predicted)
形态缓冲水溶液
Merck13,6329
BRN4220745
常见问题列表
概述
佐剂肽是指一种通过诱发、加强和/或促进针对抗原的免疫反应来促进或调节抗原功能而作为功能性组分(组合物中)的肽。用途
佐剂肽主要用于医药、化工领域。生物活性
Muramyl dipeptide (MDP) 是肽聚糖的共有结构单元。Muramyl dipeptide 通过诱导 Runx2 来诱导 bone formation。靶点
| Target | Value |
|
Runx2
() |
体外研究
Muramyl dipeptide (0.1-10 µg/mL; 24 hours) increases protein expression of Runx2 in a dose-dependent manner.
Muramyl dipeptide (0.1-10 µg/mL; 6 hours) increases mRNA levels of Runx2 in a dose-dependent manner.
Western Blot Analysis
| Cell Line: | MC3T3-E1 cells |
| Concentration: | 0.1, 1, 10 µg/mL |
| Incubation Time: | 24 hours |
| Result: | Increased protein expression of Runx2 in a dose-dependent manner. |
RT-PCR
| Cell Line: | MC3T3-E1 cells |
| Concentration: | 0.1, 1, 10 µg/mL |
| Incubation Time: | 6 hours |
| Result: | Increases mRNA levels of Runx2 in a dose-dependent manner. |
体内研究
Muramyl dipeptide (1.25 mg/kg; i.p.; twice) alleviates bone loss induced by osteoporosis.
| Animal Model: | RANKL-induced osteoporosis model (Five-week-old C57BL/6 mice) |
| Dosage: | 1.25 mg/kg |
| Administration: | i.p.; twice (RANKL-induced osteoporosis for 3 weeks and euthanized at 4 weeks) |
| Result: | Significantly enhanced the trabecular bone volume (BV/TV) and trabecular number (Tb.N). |